Atorvastatin vs Rosuvastatin in the Prevention of Cardiovascular Events: A Systematic Review

Hyder Osman Mirghani; Khalid Mofareh A Asiri; Saud Hassan S Hussain; Mohammed Abdullah Alqahtani; Rand Fahad M Albaridi; Khaled Yahya A Hader; Mohammed Faris S Alanzi; Rimaz Jameel Aljohani; Raghad Saleh M Alqarni; Norah Abdulaziz Alturki; Rayan Khalid R Albalawi; Fai Yahya Sayd; Manar Saleem E Alhawi

doi:10.54293/smhj.v4i3.116

Authors

Hyder Osman Mirghani Prof. of Internal Medicine and Endocrine, Department of Internal Medicine, Faculty of Medicine, University of Tabuk, KSA. https://orcid.org/0000-0002-5817-6194
Khalid Mofareh A Asiri Medical Student, College of Medicine, King Khalid University, Asir, KSA.
Saud Hassan S Hussain Medical Student, College of Medicine, King Khalid University, Asir, KSA. https://orcid.org/0009-0004-3046-8293
Mohammed Abdullah Alqahtani Medical Student, College of Medicine, King Khalid University, Asir, KSA. https://orcid.org/0009-0001-9468-1817
Rand Fahad M Albaridi Medical Student, Faculty of Medicine, University of Tabuk, Tabuk, KSA. https://orcid.org/0009-0001-4972-307X
Khaled Yahya A Hader Medical Student, College of Medicine, King Khalid University, Asir, KSA. https://orcid.org/0009-0003-4923-5847
Mohammed Faris S Alanzi Medical Student, Faculty of Medicine, University of Tabuk, Tabuk, KSA.
Rimaz Jameel Aljohani Medical Student, Faculty of Medicine, University of Tabuk, Tabuk, KSA. https://orcid.org/0009-0006-7862-1204
Raghad Saleh M Alqarni Pharmacy Student, Faculty of Pharmacy, University of Tabuk, Tabuk, KSA.
Norah Abdulaziz Alturki Medical Student, Faculty of Medicine, University of Tabuk, Tabuk, KSA.
Rayan Khalid R Albalawi Medical Student, Faculty of Medicine, University of Tabuk, Tabuk, KSA.
Fai Yahya Sayd Pharmacy Student, Faculty of Pharmacy, University of Tabuk, Tabuk, KSA.
Manar Saleem E Alhawi Pharmacy Student, Faculty of Pharmacy, University of Tabuk, Tabuk, KSA.

DOI:

https://doi.org/10.54293/smhj.v4i3.116

Keywords:

Keywords: Statins; Atorvastatin; Rosuvastatin; Cardiovascular disease; Coronary syndrome; Systematic review.

Abstract

The main objective of this study is to compare any differences in the clinical response to rosuvastatin and atorvastatin in patients with cardiovascular disease. PubMed, SCOPUS, Web of Science, Science Direct, and Clinical Key were systematically searched for relevant literature. Rayyan QRCI was employed throughout this comprehensive process. We included eleven studies with a total of 6168 patients; 3231 (52.4%) patients received Atorvastatin, and 2937 (47.6%) received Rosuvastatin. Regarding ACS patients, Rosuvastatin outperformed Atorvastatin in improving laboratory indices and inflammatory markers and lowering LDL. In STEMI patients undergoing PCI, Atorvastatin was linked to less dysfunctional coronary circulation, better coronary microcirculation in patients with STEMI having primary PCI, and may enhance microvascular coronary perfusion immediately following PCI more effectively than a high-dose rosuvastatin preloading. The one study included patients undergoing CABG and did not find any differences between Atorvastatin and Rosuvastatin in preventing post-CABG atrial fibrillation (AF). These results suggest that when developing treatment plans for patients with cardiovascular disease, physicians may be able to combine atorvastatin with rosuvastatin. Cost considerations, tolerability, and patient-specific characteristics should all be taken into account during the decision-making process.